ClinicalTrials.gov record
Completed Phase 2Phase 3 Interventional Results available

Selinexor in Advanced Liposarcoma

ClinicalTrials.gov ID: NCT02606461

Public ClinicalTrials.gov record NCT02606461. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 17, 2026, 3:17 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2-3, Multicenter, Randomized, Double-blind Study of Selinexor (KPT-330) Versus Placebo in Patients With Advanced Unresectable Dedifferentiated Liposarcoma (DDLS)

Study identification

NCT ID
NCT02606461
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2, Phase 3
Lead sponsor
Karyopharm Therapeutics Inc
Industry
Enrollment
342 participants

Conditions and interventions

Interventions

  • Placebo Drug
  • Selinexor Drug

Drug

Eligibility (public fields only)

Age range
12 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jan 3, 2016
Primary completion
Oct 27, 2020
Completion
Oct 25, 2021
Last update posted
Jan 22, 2023

2016 – 2021

United States locations

U.S. sites
26
U.S. states
18
U.S. cities
21
Facility City State ZIP Site status
Cedars-Sinai Medical Center Los Angeles California 90048
University of California, Los Angeles Los Angeles California 90095
Sarcoma Oncology Center Santa Monica California 90403
Stanford University Stanford California 94305
University of Colorado-Denver Denver Colorado 80202
Yale Cancer Center New Haven Connecticut 06520-8032
Mayo Clinic Jacksonville Florida 32224
Northwestern Memorial Hospital Chicago Illinois 60611
Johns Hopkins Baltimore Maryland 21231
Massachusetts General Hospital Boston Massachusetts 02114
Dana Farber Cancer Institute Boston Massachusetts 02215
University of Michigan Ann Arbor Michigan 48109
Mayo Clinic Rochester Rochester Minnesota 55905
Washington University School of Medicine St Louis Missouri 63110
Columbia University Medical Center New York New York 10032
Memorial Sloan Kettering Cancer Center New York New York 10065
Northwell Health Physicians Partners New York New York 11042
Duke Institute of Cancer Durham North Carolina 27710
James Cancer Center, Ohio State University Columbus Ohio 43210-1240
Oregon Health and Science Portland Oregon 97239
University of Pennsylvania Philadelphia Pennsylvania 19106
Fox Chase Cancer Center Philadelphia Pennsylvania 19111
University of Pittsburgh Medical Center (UPMC) Pittsburgh Pennsylvania 15232
Vanderbilt Nashville Tennessee 37232
MD Anderson Houston Texas 77030
Fred Hutchinson Cancer Research Center Seattle Washington 98109

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 45 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02606461, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jan 22, 2023 · Synced May 17, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02606461 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →